Answers are grounded in this paper and cite their sources.
Retrospective analysis shows improved outcomes in lupus nephritis patients after rituximab treatment, suggesting its efficacy and safety.
Treatment-resistant lupus nephritis (LN) is a challenging condition, often causing significant morbidity. While midterm outcomes of anti-CD20 therapies are well-studied, their long-term effects remain unclear. To assess Rituximab's long-term efficacy and safety in patients with refractory LN. The study, conducted retrospectively at a single centre between 2010-2022, included lupus nephritis patients who met the American College of Rheumatology's criteria for SLE. We evaluated 24-hour proteinuria, creatinine clearance, serum creatinine, and SLEDAI-2K, before and after rituximab treatment. The primary endpoints as a response to treatment were defined as the attainment of a prednisolone dose of 5mg and 24-hour proteinuria of 500mg. Additionally, we investigated any adverse effects of Rituximab. Patients (34 females, 13 males; mean age 42.3 years; mean disease duration 10.4 years) received a median 3 of rituximab courses. Before treatment, median amount of proteinuria was 3050mg/day. Following the final course of rituximab, the median amount of proteinuria significantly decreased to 747mg/day (p<0.001). SLEDAI-2K score also reduced significantly, from 16.3±6.2 to 7.2±4.8 (p<0.001). The mean steroid dose in the final rituximab course was 7.5±5.8 mg/day (p<0.001), compared to the initial dose of 24.13±18.47mg/day. At primary endpoint, 53.1% of patients achieved a prednisolone dose of 5mg, 36.1% had a 24-hour proteinuria level of 500mg, and 25.5% met both criteria. Rituximab significantly improved disease activity in lupus nephritis patients, reducing proteinuria, SLEDAI-2K scores, and allowing for steroid dose reduction. Given its efficacy and safety, rituximab may be a promising option for patients resistant to conventional therapy.
No takes yet. Share an insight, caveat, or question.
Şentürk et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: